Som med anden anti- HIV- medicin kan patienter, der tager Epivir, have risiko for at udvikle lipodystrofi (ændringer i fordelingen af kropsfedt), osteonekrose (henfald af knoglevævet) eller immunt reaktiveringssyndrom (symptomer på infektion forårsaget af genopretning af immunsystemet).
As with other anti-HIV medicines, patients taking Epivir may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).